Iain Ross - 02 Jan 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Reporting relationship
Director
Issuer ticker
SLN
Reported as of
02 Jan 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
02 Jan 2025, 16:38:35 UTC
Next SEC filing
22 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Rhonda Hellums, Attorney-in-Fact

Key filing fact

Iain Ross filed Form 3 for Silence Therapeutics plc (SLN) on 02 Jan 2025.

Key facts

  • This page summarizes Iain Ross's Form 3 filing for Silence Therapeutics plc (SLN).
  • 0 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 02 Jan 2025, 16:38.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
39,942
Date
02 Jan 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
250,000
Exercise price
$0.8000
Footnotes
F1
SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
250,000
Exercise price
$2.53
Footnotes
F1
SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
150,000
Exercise price
$0.0700
Footnotes
F1
SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
350,000
Exercise price
$5.87
Footnotes
F1
SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
90,000
Exercise price
$7.87
Footnotes
F2
SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
90,000
Exercise price
$5.13
Footnotes
F3
SLN holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Jan 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
90,000
Exercise price
$5.90
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Immediately exercisable.

Footnote F2

This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

Footnote F3

This option vested or shall vest in equal monthly installments over a three-year period measured from one month following September 14, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.

Footnote F4

This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 4, 2024, subject to the Reporting Person's continuous service as of the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .